JPMorgan raised the firm’s price target on Alnylam (ALNY) to $338 from $330 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect higher Amvuttra estimates.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections
- Alnylam receives European Commission approval of AMVUTTRA
- Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook
- Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
- Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements